Porous silicon microparticles for delivery of siRNA therapeutics.

PubWeight™: 0.78‹?›

🔗 View Article (PMID 25651103)

Published in J Vis Exp on January 15, 2015

Authors

Jianliang Shen1, Xiaoyan Wu2, Yeonju Lee3, Joy Wolfram4, Zhizhou Yang3, Zong-Wan Mao5, Mauro Ferrari6, Haifa Shen7

Author Affiliations

1: Department of Nanomedicine, Houston Methodist Research Institute; MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry and Chemical Engineering, Sun Yat-sen University.
2: Department of Nanomedicine, Houston Methodist Research Institute; Pediatrics Department of Union Hospital, Huazhong University of Science and Technology.
3: Department of Nanomedicine, Houston Methodist Research Institute.
4: Department of Nanomedicine, Houston Methodist Research Institute; CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, National Center for Nanoscience & Technology of China.
5: MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry and Chemical Engineering, Sun Yat-sen University.
6: Department of Nanomedicine, Houston Methodist Research Institute; Department of Medicine, Weill Cornell Medical College.
7: Department of Nanomedicine, Houston Methodist Research Institute; Department of Cell and Developmental Biology, Weill Cornell Medical College; hshen@houstonmethodist.org.

Articles cited by this

Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov (2009) 12.46

Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov (2007) 6.37

Nonviral vectors for gene delivery. Chem Rev (2009) 4.08

Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release (2009) 3.08

siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev (2009) 2.21

Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat Nanotechnol (2010) 2.17

Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. Adv Drug Deliv Rev (2006) 1.95

Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials (2007) 1.72

Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity. Bioconjug Chem (2008) 1.62

Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med (2010) 1.36

Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res (2013) 1.21

Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. Small (2013) 1.05

High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics. ACS Nano (2013) 0.98

Degradation and biocompatibility of multistage nanovectors in physiological systems. J Biomed Mater Res A (2013) 0.90

Polycation-functionalized nanoporous silicon particles for gene silencing on breast cancer cells. Biomaterials (2013) 0.85

Dose-dependent movement of cationic molecules across the glomerular wall. Anat Rec (1985) 0.84

Gene medicines: the end of the beginning? Adv Drug Deliv Rev (2005) 0.83